ABBVIE INC (NYSE: ABBV)

ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

最近更新时间: 2天之前, 11:10AM

207.63

2.34 (1.14%)

加入群组

前收盘价格	205.29
收盘价格	204.43
成交量	3,081,317
平均成交量 (3个月)	6,329,994
市值	367,284,453,376

市盈率 (P/E TTM)	87.24
预期市盈率 (P/E Forward)	16.72
价格/销量 (P/S)	6.46
股市价格/股市净资产 (P/B)	109.22

52周波幅	153.58 (-26%) — 218.66 (5%)
利润日期	25 Apr 2025
股息率 (DY TTM)	3.03%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	混合的	看涨
	Drug Manufacturers - General (全球的)	混合的	看涨
股票	AbbVie Inc.	看涨	看涨

AIStockmoo 评分

0.1

分析师共识	1.5
内部交易活动	NA
价格波动	-0.5
技术平均移动指标	0.0
技术振荡指标	-0.5
平均	0.13

相关股票

股票	市值	DY	P/E（TTM）	P/B
ABBV	367 B	3.03%	87.24	109.22
JNJ	374 B	3.19%	26.83	5.50
PFE	140 B	6.84%	17.52	1.58
BMY	122 B	4.03%	-	7.64
GSK	70 B	4.54%	23.00	4.47
LLY	735 B	0.66%	69.93	52.04

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.10%
机构持股比例	73.94%

52周波幅	153.58 (-26%) — 218.66 (5%)
目标价格波幅	190.00 (-8%) — 240.00 (15%)
高	240.00 (Wells Fargo, 15.59%)	购买
中	217.00 (4.52%)
低	190.00 (UBS, -8.49%)	保留
平均值	219.22 (5.59%)
总计	7 购买, 2 保留
平均价格@调整类型	194.48

公司	日期	目标价格	调整类型	价格@调整类型
Wells Fargo	05 Mar 2025	240.00 (15.59%)	购买	211.54
Wells Fargo	03 Feb 2025	210.00 (1.14%)	购买	190.14
B of A Securities	04 Mar 2025	223.00 (7.41%)	保留	207.76
BMO Capital	03 Feb 2025	215.00 (3.55%)	购买	190.14
Citigroup	03 Feb 2025	215.00 (3.55%)	购买	190.14
Citigroup	28 Jan 2025	205.00 (-1.26%)	购买	174.81
Guggenheim	03 Feb 2025	214.00 (3.07%)	购买	190.14
Morgan Stanley	03 Feb 2025	239.00 (15.11%)	购买	190.14
Raymond James	03 Feb 2025	220.00 (5.96%)	购买	190.14
Truist Securities	03 Feb 2025	217.00 (4.52%)	购买	190.14
Truist Securities	08 Jan 2025	211.00 (1.63%)	购买	178.50
UBS	03 Feb 2025	190.00 (-8.49%)	保留	190.14
显示更多

该时间范围内无数据。

日期	类型	细节
31 Mar 2025	公告	AbbVie to Host First-Quarter 2025 Earnings Conference Call
26 Mar 2025	公告	AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
24 Mar 2025	公告	Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
15 Mar 2025	公告	ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
11 Mar 2025	CNBC	Ad spending on women's sports more than doubled last year
04 Mar 2025	公告	AbbVie to Present at the Leerink Partners Global Healthcare Conference
03 Mar 2025	公告	AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
28 Feb 2025	公告	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
26 Feb 2025	公告	AbbVie to Present at the TD Cowen's 45th Annual Health Care Conference
14 Feb 2025	公告	AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
13 Feb 2025	公告	AbbVie Declares Quarterly Dividend
12 Feb 2025	公告	Allergan Aesthetics To Launch Three New State-of-the-Art Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training
12 Feb 2025	公告	AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
12 Feb 2025	公告	AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
07 Feb 2025	公告	U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
06 Feb 2025	公告	Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
05 Feb 2025	公告	Allergan Aesthetics, the American Society of Plastic Surgeons (ASPS) and The Aesthetic Society Release Two New Engaging LIMITLESS Videos Celebrating Women Surgeons
31 Jan 2025	公告	AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
29 Jan 2025	公告	Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
24 Jan 2025	公告	Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
23 Jan 2025	公告	AbbVie Completes Acquisition of Nimble Therapeutics
23 Jan 2025	公告	AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
17 Jan 2025	CNBC	Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
13 Jan 2025	公告	AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
13 Jan 2025	公告	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology
13 Jan 2025	公告	AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
09 Jan 2025	公告	AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 Jan 2025	公告	CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
03 Jan 2025	公告	AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
显示更多

股息率 (DY TTM)	3.03%
5年平均股息收益率	3.81%
股息支付比率	259.41%
预计下次股息支付	Aug 2025

除息日	公告日期	支付日期	详情
15 Apr 2025	13 Feb 2025	15 May 2025	1.64 现金
15 Jan 2025	30 Oct 2024	14 Feb 2025	1.64 现金
15 Oct 2024	06 Sep 2024	15 Nov 2024	1.55 现金
15 Jul 2024	20 Jun 2024	15 Aug 2024	1.55 现金
12 Apr 2024	15 Feb 2024	15 May 2024	1.55 现金
12 Jan 2024	27 Oct 2023	15 Feb 2024	1.55 现金
12 Oct 2023	08 Sep 2023	15 Nov 2023	1.48 现金
13 Jul 2023	22 Jun 2023	15 Aug 2023	1.48 现金
13 Apr 2023	16 Feb 2023	15 May 2023	1.48 现金
12 Jan 2023	28 Oct 2022	15 Feb 2023	1.48 现金
13 Oct 2022	09 Sep 2022	15 Nov 2022	1.41 现金
14 Jul 2022	23 Jun 2022	15 Aug 2022	1.41 现金
13 Apr 2022	17 Feb 2022	16 May 2022	1.41 现金
13 Jan 2022	29 Oct 2021	15 Feb 2022	1.41 现金
14 Oct 2021	10 Sep 2021	15 Nov 2021	1.3 现金
14 Jul 2021	17 Jun 2021	16 Aug 2021	1.3 现金
14 Apr 2021	18 Feb 2021	14 May 2021	1.3 现金
14 Jan 2021	30 Oct 2020	16 Feb 2021	1.3 现金
14 Oct 2020	11 Sep 2020	16 Nov 2020	1.18 现金
14 Jul 2020	17 Jun 2020	14 Aug 2020	1.18 现金
14 Apr 2020	20 Feb 2020	15 May 2020	1.18 现金
14 Jan 2020	01 Nov 2019	14 Feb 2020	1.18 现金
11 Oct 2019	06 Sep 2019	15 Nov 2019	1.07 现金
12 Jul 2019	21 Jun 2019	15 Aug 2019	1.07 现金
12 Apr 2019	22 Feb 2019	15 May 2019	1.07 现金
14 Jan 2019	02 Nov 2018	15 Feb 2019	1.07 现金
12 Oct 2018	08 Sep 2018	15 Nov 2018	0.96 现金
12 Jul 2018	15 Jun 2018	15 Aug 2018	0.96 现金
12 Apr 2018	15 Feb 2018	15 May 2018	0.96 现金
11 Jan 2018	27 Oct 2017	15 Feb 2018	0.71 现金
12 Oct 2017	08 Sep 2017	15 Nov 2017	0.64 现金
12 Jul 2017	22 Jun 2017	15 Aug 2017	0.64 现金
11 Apr 2017	16 Feb 2017	15 May 2017	0.64 现金
11 Jan 2017	28 Oct 2016	15 Feb 2017	0.64 现金
12 Oct 2016	09 Sep 2016	15 Nov 2016	0.57 现金
13 Jul 2016	16 Jun 2016	15 Aug 2016	0.57 现金
13 Apr 2016	18 Feb 2016	16 May 2016	0.57 现金
13 Jan 2016	30 Oct 2015	16 Feb 2016	0.57 现金
13 Oct 2015	11 Sep 2015	16 Nov 2015	0.51 现金
13 Jul 2015	18 Jun 2015	14 Aug 2015	0.51 现金
13 Apr 2015	19 Feb 2015	15 May 2015	0.51 现金
13 Jan 2015	20 Oct 2014	13 Feb 2015	0.49 现金
10 Oct 2014	19 Sep 2014	17 Nov 2014	0.42 现金
11 Jul 2014	19 Jun 2014	15 Aug 2014	0.42 现金
11 Apr 2014	20 Feb 2014	15 May 2014	0.42 现金
13 Jan 2014	12 Dec 2013	14 Feb 2014	0.4 现金
10 Oct 2013	19 Sep 2013	15 Nov 2013	0.4 现金
11 Jul 2013	20 Jun 2013	15 Aug 2013	0.4 现金
11 Apr 2013	15 Feb 2013	15 May 2013	0.4 现金
11 Jan 2013	04 Jan 2013	15 Feb 2013	0.4 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	3.28	2	1.58
2024	6.20	4	3.49
2023	5.92	4	3.82
2022	5.64	4	3.49
2021	5.20	4	3.84
2020	4.72	4	4.41
2019	4.28	4	4.83
2018	3.59	4	3.89
2017	2.56	4	2.65
2016	2.28	4	3.64
2015	2.02	4	3.41
2014	1.66	4	2.54
2013	1.60	4	3.03
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2025	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	7.59%
营业利益率 (TTM)	36.66%
稀释每股收益 (EPS TTM)	2.38
季度收入增长率 (YOY)	5.60%
季度盈利增长率 (YOY)	-12.20%

总债务/股东权益 (D/E MRQ)	2,021.97%
流动比率 (MRQ)	0.660
营业现金流 (OCF TTM)	18.81 B
杠杆自由现金流 (LFCF TTM)	19.98 B

资产报酬率 (ROA TTM)	8.49%
股东权益报酬率 (ROE TTM)	62.29%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)